---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-039986"
form_type: "8-K"
ticker: "XTNT"
cik: "0001453593"
company_name: "Xtant Medical Holdings, Inc."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T06:26:44.568207+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Xtant Medical reports record Q3 revenue of $25M, raises FY2023 guidance to $88M-$91M

## Summary
- Revenue $25.0M, +73% YoY; organic growth 18%; acquisition contributions 55%.
- Net income $9.2M ($0.07 EPS) vs net loss $2.4M ($0.03 loss) in Q3 2022.
- Non-GAAP adjusted EBITDA $0.5M, improved from -$0.9M in prior-year period.
- Gross margin expanded to 61.3% from 54.6% on production efficiencies and product mix.
- FY2023 revenue guidance raised to $88M-$91M from prior $75M-$77M.

## SEC filing metadata
- accession: 0001493152-23-039986
- form_type: 8-K
- ticker: XTNT
- cik: 0001453593
- company_name: Xtant Medical Holdings, Inc.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1453593/000149315223039986/0001493152-23-039986-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1453593/000149315223039986/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-039986
- JSON: https://secwatch.observer/filing/0001493152-23-039986.json
- Plain text: https://secwatch.observer/filing/0001493152-23-039986.txt

## Key facts
- Earnings Releases
  Xtant Medical Holdings, Inc. reported third quarter ended September 30, 2023 results: revenue $25.0 million, net income $9.2 million, or $0.07 per share, EPS $0.07 per share. Guidance raised.
  - Period: third quarter ended September 30, 2023
  - Revenue: $25.0 million
  - Net income: $9.2 million, or $0.07 per share
  - EPS: $0.07 per share
  - Guidance: raised
  - Result: reported results
  source text: Xtant Medical Announces Record Third Quarter Revenue of $25 Million Raises 2023 Annual Revenue Guidance to $88 Million - $91 Million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1453593/000149315223039986/0001493152-23-039986-index.htm
- Earnings Releases
  Xtant Medical Holdings, Inc. updated its full year 2023 guidance (raised).
  - Period: full year 2023
  - Guidance: raised
  - Result: guidance update
  source text: Xtant Medical raises its expectation for full year 2023 revenue to $88 million to $91 million, up from the Company’s prior guidance of $75 million to $77 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1453593/000149315223039986/0001493152-23-039986-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.